Download PDF
Klin Monbl Augenheilkd 2012; 229(4): 441-442
DOI: 10.1055/s-0031-1299253
Der interessante Fall
© Georg Thieme Verlag KG Stuttgart · New York

Paecilomyces Lilacinus Endophthalmitis following Cataract Surgery: A Therapeutic Challenge

Pilzendophthalmitis durch Paecilomyces lilacinus nach Kataraktoperation: eine therapeutische Herausforderung
S. Trachsler
1   Dept. of Ophthalmology, UniversityHospital of Zurich, Switzerland
,
R. Eberhard
1   Dept. of Ophthalmology, UniversityHospital of Zurich, Switzerland
,
C. Kocher
2   Dept. of Infectiology, UniversityHospital of Zurich, Switzerland
,
J. Fleischhauer
1   Dept. of Ophthalmology, UniversityHospital of Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
11 April 2012 (online)

Also available at
    Permissions and Reprints

Background

Paecilomyces lilacinus are ubiquitous saprophytic fungi found in decomposing plants and soil. It rarely contaminates biomaterial but half of all reported infections affect ocular structures [1]. Infection is usually exogenous [2] [3] [4]. Paecilomyces lilacinus often shows multiple resistance to antimycotics [1]. Successful treatment has been reported using voriconazole [5] [6].

 

  • References

  • 1 Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948-960
    CrossrefPubMedGoogle Scholar
  • 2 Rodrigues MM, MacLeod D. Exogenous fungal endophthalmitis caused by Paecilomyces. Am J Ophthalmol 1975; 79: 687-690
    PubMedGoogle Scholar
  • 3 Ando N, Yamamoto T, Nakajima H et al. Oculomycosis caused by Paecilomyces lilacinus. Rinsho Ganka 1979; 33: 217-223
    PubMedGoogle Scholar
  • 4 Takatsuki R, Uchihori T, Tomiyoshi Y et al. Oculomycosis caused by Paecilomyces lilacinus. Rinsho Ganka 1984; 38: 561-564
    PubMedGoogle Scholar
  • 5 Garbino J, Ondrusova A, Baglivo E et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34 (09) 701-703
    CrossrefPubMedGoogle Scholar
  • 6 Shen YC, Wang CY, Tsai HY et al. Intracameral Voriconazole Injection in the Treatment of Fungal Endophthalmitis Resulting From Keratitis. Am J Ophthalmol 2010; 149: 916-921
    CrossrefPubMedGoogle Scholar
  • 7 Kernt M, Kampik A. Intracameral voriconazole: in vivo safety for human ocular cells. Toxicology 2009; 258 (02–3) 84-93
    CrossrefPubMedGoogle Scholar
  • 8 Wei LC, Tsai SC, Tsai HY et al. Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application. Curr Eye Res 2010; 35 (07) 573-579
    CrossrefPubMedGoogle Scholar
  • 9 Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42-47
    CrossrefPubMedGoogle Scholar
  • 10 Shen YC, Wang MY, Wang CY et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53 (05) 2156-2157
    CrossrefPubMedGoogle Scholar